TABLE 3.
comparison of the 190 KTRs and 56 controls included in the study.
| Variable Name | All | KTR (190) | Control (56) | p | |||
|---|---|---|---|---|---|---|---|
| Age (years) (Mean, SD) | 61.36 | 11.940 | 59.03 | 12.355 | 69.27 | 5.303 | <0.001 |
| Female gender (No., percentage) | 88 | 35.77% | 61 | 32.11% | 27 | 48.21% | 0.027 |
| Diabetes mellitus (No., percentage) | 44 | 17.89% | 37 | 19.47% | 7 | 12.50% | 0.231 |
| BMI (kg/m2) (mean, SD) | 27.0828 | 4.229 | 27.22 | 4.431 | 26.60 | 3.400 | 0.35 |
| Serum creatinine (mg/dl) (mean, SD) | 1.25 | 0.733 | 1.36 | 0.790 | 0.86 | 0.207 | <0.001 |
| Time to booster dose a (mean, SD) | 172.17 | 23.222 | 163.38 | 18.410 | 201.85 | 8.468 | <0.001 |
| Bassline antibody level (AU/ml) (median, IQR) | 52.75 | 3.68–343 | 13.80 | 2.6–111.55 | 514.35 | 259.68–857.8 | <0.001 |
| Antibody levels after third dose (AU/ml) (median, IQR) | 1881.45 | 59.48–13,299.2 | 622.40 | 19.35–5,474.4 | 23,800.15 | 13,343–41,511.75 | <0.001 |
| Baseline log antibody level (AU/ml) (mean, SD) | 1.62 | 0.99 | 1.31 | 0.90 | 2.65 | 0.40 | <0.001 |
| Log antibody level after third dose (mean, SD) | 2.92 | 1.432 | 2.51 | 1.365 | 4.31 | 0.417 | <0.001 |
| Adjusted log antibody level after third dose b (median, IQR) | — | — | 2.32 | 3.7–4.63 | 4.17 | 2.07–2.56 | <0.001 |
| Antibody level above 50 AU/ml (No., percentage) | 189 | 76.8% | 133 | 70.0% | 56 | 100.0% | <0.001 |
| Antibody level above 4160 AU/ml (No., percentage) | 104 | 42.3% | 52 | 27.4% | 52 | 92.9% | <0.001 |
IQR, interquartile range.
a
Time between the second and third vaccine dose in days.
b
Estimated marginal mean with 95% CI, adjusted for age, gender; BMI, serum creatinine and diabetes mellitus.